CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Details) $ in Thousands	3 Months Ended	9 Months Ended
Dec. 31, 2016 USD ($) investment	Sep. 30, 2018 USD ($)	Sep. 30, 2017 USD ($)
Schedule of Equity Method Investments [Line Items]
Number of equity method investments sold \| investment	1
Gain on sale of investment in unconsolidated affiliate		$ 308	$ 733
Unnamed pharmacy joint venture
Schedule of Equity Method Investments [Line Items]
Gain on sale of investment in unconsolidated affiliate	$ 1,366	$ 308	$ 733

Amount of gain (loss) on sale or disposal of an equity method investment.

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(b)(7)(c))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(b)(9)(a))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Name:	us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration